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ABSTRACT
INTRODUCTION: Up to 60% of people infected with SARS-CoV-2 report anosmia 
or ageusia during their disease course. “COVID Smell Tracker” is a smart phone 
application (app) developed to elucidate the onset, duration and extent of 
anosmia and ageusia through questionnaires.  
METHODS: “COVID Smell Tracker” is publicly available on smart phone devices 
(www.covidsmelltracker.org). Users complete surveys around demographics, 
medical history, COVID status and symptomology. Deidentified responses were 
collated and analyzed using descriptive statistics.
RESULTS: Of the 266 users included, the majority were located in Europe (43%) 
and North America (33%). Male, Caucasian users were most common (54.9% and 
61.7% respectively), followed by Indian (10.5%) and Latino (9.4%). The majority 
of users reported no COVID testing (63%). 164 users reported COVID-related 
symptoms, and 57% of them reported olfactory dysfunction. Users whom 
were younger age (p = 0.0003) and with type A and B blood types (p = 
0.021) experienced smell loss at higher frequencies. Dysgeusia was associated 
with 28-34% of patients with concomitant smell loss, versus 6%-9% in users 
without. Smell loss was described as “sudden” (63%), occurring on average 3 days 
following the onset of any other symptom. Of those that reported resolution of 
their smell loss, 50% resolved in 1 week, with 75% resolution reported within 1 
month.
CONCLUSION: The results herein correlate with other established COVID-
related studies, despite relying on purely volunteered data from 
participants from around the world. This is the first study to suggest an 
association of age and blood type with smell loss. Mobile app use offers a novel 
method for safe, remote and granular insight into those suffering from infectious 
diseases like COVID-19.
OBJECTIVE
SPECIFIC AIM: The ultimate objective of
this study is to uncover more about the
epidemiology and prognosis of those
suffering to allow physicians to
appropriately manage COVID-related




§ Prospectively collected data from
the corresponding author’s mobile
application (COVID Smell Tracker)
was analyzed over an 8-month
period from May in 2020 to
February 2021.
§ Data was exported and user data
were grouped by demographics,
COVID symptoms, medical history,
and treatment history. Subjective
symptom scoring was recorded as
a twenty-two item Sinonasal
Outcomes Test (SNOT-22).
§ Deidentified responses were
collated and analyzed using
descriptive statistics.
SUMMARY
§ The data generated within Figure 1 and Table 1
encompasses users from every inhabited continent,
marking this as one of the first studies to
incorporate a global patient pool.
§ The incidence of smell loss amongst symptomatic
users was measured at 57% and occurred on
average within 3 days of symptom onset.
§ Table 2 indicated that almost half of patients
reported smell resolution at one week, and
additional 20% reporting resolution at two weeks.
However, there were approximately 25% of patients
that resolved beyond one month and even over 6
months.
§ Figure 2 and Figure 3 did indicate that smell loss
may disproportionately affect younger people and
those with particular blood types.
§ Figure 2 shows that younger users (34.6 years vs
41.7 years) experienced higher rates of smell loss
amongst all symptomatic users.
§ Figure 3 shows blood type B was over 2.5 times
more likely to have concomitant smell loss,
versus blood type O which almost half as likely.
User Map
Distribution of Smell Loss by Blood Type
FIGURE 3: Type O and Type A blood were the most prevalent blood types. Those with A, B or AB blood type
experienced higher rates of smell loss amongst all symptomatic users. Specifically, blood type B was over
2.5 times more likely, versus blood type O which almost half as likely.
CONCLUSION
§ COVID Smell Tracker may be used in
parallel with other, validated clinical
assessments to track disease
incidence, risk factors, infection
trends and outcomes on a global
scale.
§ This app can provide additional
longitudinal information to the
epidemiological community by
collecting data on a remote platform.
§ Data from the present analysis
suggest there may be a correlation
between age, blood type and the
experience of smell loss from COVID-
19.
§ Future age-matched multivariate
studies should be conducted to
investigate this relationship further.
Distribution of Age Amongst Symptomatic Users
FIGURE 2: The average user was 39.5 years of age, 54.9% male and 45.1%
female. Younger users (34.6 years vs 41.7 years) experienced higher rates of
smell loss amongst all symptomatic users.
User Demographics
FIGURE 1, TABLE 1, and TABLE 2: Subjective data was captured from users from all across the world. The majority of users were from Europe
(43%), followed by North America (32.6%), Asia (15.7%), South America (5.2%), and Australia (0.4%). The average user was 39.5 years of age, 54.9%
male and 45.1% female. By race, the majority of users identified as Caucasian (61.7%), followed by Asian Indians (10.5%), and Latinos (9.4%). The
remainder of the demographic data can be visualized in Table 1. Table 2 shows that 48.3% patients reported smell resolution at one week, 20%
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